Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary

Arcus Biosciences, Inc. (NYSE:RCUS) Grants Equity Awards to New Employees

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an exercise price per share of $15.77, which was the closing price on December 8, 2023, and restricted stock units to acquire a total of 9,800 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2α. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20231211927519/en/

Investor Inquiries:

Pia Banerjee

Head of Investor Relations & Strategy

(617) 459-2006

pbanerjee@arcusbio.com

Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

How many new employees were granted equity awards by Arcus Biosciences, Inc. (NYSE:RCUS)?

Six new employees were granted equity awards by Arcus Biosciences, Inc. (NYSE:RCUS).

How many shares of the Company's common stock were the new employees granted options to purchase?

The new employees were granted options to purchase a total of 19,600 shares of the Company's common stock.

At what exercise price per share were the new employees granted options to purchase the Company's common stock?

The exercise price per share was $15.77, which was the closing price on December 8, 2023.

How many restricted stock units were granted to the new employees by Arcus Biosciences, Inc. (NYSE:RCUS)?

A total of 9,800 shares of the Company's common stock in the form of restricted stock units were granted to the new employees.

Under which plan were the equity awards granted to the new employees by Arcus Biosciences, Inc. (NYSE:RCUS)?

The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020.

What is the purpose of the Company's 2020 Inducement Plan?

The 2020 Inducement Plan was approved pursuant to the 'inducement exception' under NYSE Listed Company Manual Rule 303A.08.